Priority 3 from the Juvenile Idiopathic Arthritis (Netherlands) PSP

UNCERTAINTY: What is the best treatment plan for uveitis in JIA, and are there factors that predict its effectiveness? (JLA PSP Priority 3)
Overall ranking 3
JLA question ID 0094/3
Explanatory note This question is specifically about uveitis in JIA, which occurs in approximately 20% of the cases of JIA. It causes a significant burden of disease, which is why it is so high in the top 10. Respondents wanted to know what the best treatment plan is for uveitis, and whether this can be predicted (linking to question 2).
Evidence

Systematic review-based + expert panel - Angeles-Han et al. 2019 American College of Rheumatology/Arthritis Foundation guidelinge for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res 2019;71:703.
Health Research Classification System category  Inflammatory and immune system
Extra information provided by this PSP
Original uncertainty examples See data spreadsheet on JLA website
Submitted by See data spreadsheet on JLA website
PSP information
PSP unique ID 0094
PSP name Juvenile Idiopathic Arthritis (Netherlands)
Total number of uncertainties identified by this PSP. 53  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 7 February 2020